Grażyna Chłoń-Rzepa

Publication Activity (10 Years)

Years Active: 2021-2022
Publications (10 Years): 4

Top Topics

Epithelial Mesenchymal Transition

Idiopathic Pulmonary Fibrosis

Major Depressive Disorder

Top Venues

Pharmacological reports : PR

Pharmaceuticals (Basel, Switzerland)

Future medicinal chemistry

This page only lists publications with an associated author ORCID identifier.

Publications

Katarzyna Wójcik-Pszczoła, Grażyna Chłoń-Rzepa, Agnieszka Jankowska, Bruno Ferreira, Paulina Koczurkiewicz, Elżbieta Pękala, Elżbieta Wyska, Krzysztof Pociecha, Reinoud Gosens
Pan-Phosphodiesterase Inhibitors Attenuate TGF-β-Induced Pro-Fibrotic Phenotype in Alveolar Epithelial Type II Cells by Downregulating Smad-2 Phosphorylation. Pharmaceuticals (Basel, Switzerland) 15 (4) (2022)
Artur Świerczek, Krzysztof Pociecha, Hanna Plutecka, Marietta Ślusarczyk, Grażyna Chłoń-Rzepa, Elżbieta Wyska
Pharmacokinetic/Pharmacodynamic Evaluation of a New Purine-2,6-Dione Derivative in Rodents with Experimental Autoimmune Diseases. Pharmaceutics 14 (5) (2022)
Małgorzata Zygmunt, Marietta Ślusarczyk, Agnieszka Jankowska, Artur Świerczek, Adrian Bryła, Szczepan Mogilski, Grzegorz Kazek, Jacek Sapa, Elżbieta Wyska, Grażyna Chłoń-Rzepa
Evaluation of analgesic and anti-inflammatory activity of purine-2,6-dione-based TRPA1 antagonists with PDE4/7 inhibitory activity. Pharmacological reports : PR 74 (5) (2022)
Agnieszka Jankowska, Grzegorz Satała, Artur Świerczek, Krzysztof Pociecha, Anna Partyka, Magdalena Jastrzębska-Więsek, Monika Głuch-Lutwin, Andrzej J Bojarski, Elżbieta Wyska, Grażyna Chłoń-Rzepa
A new class of 5-HT1A receptor antagonists with procognitive and antidepressant properties. Future medicinal chemistry 13 (18) (2021)